Arch Therapeutics

OverviewSuggest Edit

Arch Therapeutics is a biotechnology company developing an innovative, elegant, and superior approach to the rapid cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care.
Arch intends to transform the landscape of interventional healthcare with products to seal and protect leaking and bleeding tissue. Arch’s solution elegantly controls the movement of these fluids and substances.
The first product, AC5 Surgical Hemostatic Device, is designed to achieve hemostasis in minimally invasive (laparoscopic) and open surgical procedures and is intended to be regulated as a medical device. Surgeons would deem the product a “must have” because of its tremendous features, making it very different and far advanced compared to anything currently on the market. AC5 stops bleeding promptly. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision directly into the wound area.

TypePrivate
Founded2006
HQFramingham, US
Websitearchtherapeutics.com

Latest Updates

Employees (est.) (Sept 2019)8
Revenue (FY, 2019)$0
Share Price (Sept 2020)$0.2 (-1%)
Cybersecurity ratingAMore

Key People/Management at Arch Therapeutics

Terrence W. Norchi

Terrence W. Norchi

Chairman of the Board of Directors, President and Chief Executive Officer
James Sulat

James Sulat

Director
Punit Dhillon

Punit Dhillon

Director
Richard E. Davis

Richard E. Davis

Chief Financial Officer
Chirag Shah

Chirag Shah

VP of R&D Engineering and Quality Systems
Daniel C. Wadsworth

Daniel C. Wadsworth

VP of Dermal Sciences
Show more

Arch Therapeutics Office Locations

Arch Therapeutics has an office in Framingham
Framingham, US (HQ)
235 Walnut St
Show all (1)

Arch Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2006

Arch Therapeutics total Funding

$5.9 m

Arch Therapeutics latest funding size

$3 m

Time since last funding

5 years ago
Arch Therapeutics's latest funding round in July 2015 was reported to be $3 m. In total, Arch Therapeutics has raised $5.9 m
Show all financial metrics

Arch Therapeutics Revenue

USD

Net income (Q3, 2020)

(904.4k)

EBIT (Q3, 2020)

(1.2m)

Cash (30-Jun-2020)

2.0m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cost of goods sold

Gross profit

General and administrative expense

36.6k1.5m3.1m3.7m4.4m5.2m4.6m4.0m
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

General and administrative expense

9.1k5.9k1.3k4.5k451.0k523.4k808.5k826.0k870.4k853.2k813.1k865.5k868.4k1.3m1.0m1.5m1.3m1.0m999.4k986.1k1.2m878.6k933.6k975.8k892.1k858.9k

R&D expense

43.8k257.2k487.1k320.3k399.7k402.5k525.1k414.0k386.3k438.6k349.3k709.9k534.6k580.9k1.0m634.0k589.2k628.8k638.7k643.7k262.4k382.8k

Operating expense total

9.1k5.9k1.3k4.5k494.8k780.7k1.3m1.1m1.3m1.3m1.3m1.3m1.3m1.7m1.4m2.2m1.8m1.6m2.0m1.6m1.8m1.5m1.6m1.6m1.2m1.2m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

4.5k557.3k833.5k4.0m5.0m6.0m4.7m2.2m

Accounts Receivable

50.0m

Prepaid Expenses

250.019.6k43.5k42.9k85.3k151.8k362.7k

Inventories

107.8k346.6k
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

5.0k19.9k3.2k52.0476.4k945.4k2.6m1.8m782.7k573.6k3.3m2.8m1.7m5.7m3.8m7.2m6.2m5.0m3.4m6.5m3.4m2.0m3.2m3.0m1.8m2.0m

Prepaid Expenses

370.0250.0250.01.1k39.6k30.9k32.2k41.8k32.4k44.1k53.0k90.1k158.0k110.1k345.2k151.3k71.4k69.9k87.7k240.0k453.1k594.5k329.5k140.7k166.3k

Inventories

200.4k954.0k977.6k

Current Assets

5.0k20.3k3.5k302.0477.5k985.0k2.7m1.8m824.4k606.0k3.3m2.9m1.8m5.9m3.9m7.6m6.3m5.0m3.4m6.6m3.6m2.4m3.8m3.6m2.9m3.2m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(36.6k)(1.9m)(8.1m)(2.9m)(6.0m)(7.8m)(4.8m)(4.5m)

Depreciation and Amortization

586.0322.01.5k5.3k8.2k

Inventories

(346.6k)

Accounts Payable

25.056.3k(138.9k)55.9k137.4k(110.0k)(103.9k)372.6k
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(10.0k)(15.9k)(1.3k)(4.5k)(892.3k)(808.4k)(9.2m)(8.8m)379.1k(454.8k)(1.9m)(1.2m)(2.4m)(4.2m)(1.4m)(3.3m)(5.0m)389.2k(1.2m)(3.4m)(2.6m)(2.4m)(3.7m)(1.7m)(2.4m)(3.3m)

Depreciation and Amortization

847.0322.0119.0477.0835.0724.01.9k3.6k1.8k3.6k6.3k1.9k3.7k5.5k

Inventories

(657.0k)(726.6k)

Accounts Payable

875.049.1k(5.2k)(210.6k)(148.8k)118.4k28.3k323.9k36.1k(96.1k)21.3k(102.6k)(247.8k)(168.8k)24.4k52.6k(81.7k)(30.3k)14.7k(53.3k)(132.0k)190.8k(231.3k)
Show all financial metrics

Arch Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Arch Therapeutics Online and Social Media Presence

Embed Graph

Arch Therapeutics News and Updates

Arch Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15 at 12 PM ET

FRAMINGHAM, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that Terrence W. Norchi, MD, Chief Executive Officer, will present at the H.C. Wainwrig…

Arch Therapeutics to Present at The LD 500 Virtual Conference on Tuesday, September 1 at 1 PM ET

FRAMINGHAM, Mass., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that Terrence W. Norchi, MD, Chief Executive Officer, will present at the LD 500 Virtual…

Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Virtual 2020 Annual Meeting Starting August 11, 2020

Emerging Technology video presentation describing swine studies using AC5-GTM for submucosal lifting and management of gastrointestinal bleeding in endoscopic resection Emerging Technology video presentation describing swine studies using AC5-GTM for submucosal lifting and management of gastrointest…

Arch Therapeutics, Inc. to Present at the Virtual Investor Fireside Chat Series

Live video moderated discussion with Dr. Terrence Norchi, CEO, on Monday, June 15, at 12:00 PM ET, immediately followed by an interactive Q&A session Live video moderated discussion with Dr. Terrence Norchi, CEO, on Monday, June 15, at 12:00 PM ET, immediately followed by an interactive Q&A …

Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5® Topical Gel Supply Chain

FRAMINGHAM, Mass., March 23, 2020 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the U.S. Food and Drug Administration (FDA) provided clearance to market AC5® Topi…

Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting on April 2, 2020

Emerging Technology podium presentation to describe swine studies using AC5-GTM for submucosal lifting and management of gastrointestinal bleeding in endoscopic resection Emerging Technology podium presentation to describe swine studies using AC5-GTM for submucosal lifting and management of gastroin…
Show more

Arch Therapeutics Blogs

Arch Therapeutics Announces $2.5 Million Registered Direct Offering

FRAMINGHAM, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that it has entered into definitive agreements with several institutional and accredited…

Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY

FRAMINGHAM, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, is scheduled to provide a corporate update today at the 2nd Annual LD Micro Big Apple Conference in Manh…

Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat

Studies highlight antimicrobial activity for AC5 technology platform; AC5™ Topical Hemostat1 under Review by Notified Body FRAMINGHAM, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic an…

Arch Therapeutics to Provide Corporate Update at the 9th Annual LD Micro Invitational

FRAMINGHAM, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 9th Annual LD Micro Invitational. The conference is bein…

Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5™ Topical Gel

FRAMINGHAM, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company submitted a 510(k) notification to the U.S. Food and Drug Administrati…

Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018

FRAMINGHAM, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the Ladenburg Thalmann 2018 Healthcare Conference. The con…
Show more

Arch Therapeutics Frequently Asked Questions

  • When was Arch Therapeutics founded?

    Arch Therapeutics was founded in 2006.

  • Who are Arch Therapeutics key executives?

    Arch Therapeutics's key executives are Terrence W. Norchi, James Sulat and Punit Dhillon.

  • How many employees does Arch Therapeutics have?

    Arch Therapeutics has 8 employees.

  • Who are Arch Therapeutics competitors?

    Competitors of Arch Therapeutics include Criam, 20/20 Gene Systems and Optimum Biologics.

  • Where is Arch Therapeutics headquarters?

    Arch Therapeutics headquarters is located at 235 Walnut St, Framingham.

  • Where are Arch Therapeutics offices?

    Arch Therapeutics has an office in Framingham.

  • How many offices does Arch Therapeutics have?

    Arch Therapeutics has 1 office.